Full Breakdown
CVS Health Under Investigation for Antitrust Violations
1/22/2026, 1:40:09 AM
Allegations of Anticompetitive Practices
A House Judiciary Committee investigation has found that CVS Health may have violated federal antitrust laws by using its pharmacy benefit manager (PBM), CVS Caremark, to threaten independent pharmacies. The inquiry, initiated in December 2024 under the leadership of Chair Jim Jordan (R-Ohio), aims to scrutinize CVS's relationships with pharmaceutical hubs—third-party online services designed to enhance patient access to specialty medications and improve price transparency. The committee's report indicates that CVS leveraged its pharmacy network contracts to suppress competition by altering its rules to prevent independent pharmacies from collaborating with these hubs.
In 2019, CVS Health reportedly developed a strategy to invest significantly in the digital pharmacy sector due to increasing competition from companies like PillPack, Phil, and Blink. The report states that CVS Health feared losing market share and subsequently took aggressive measures to eliminate outside competition by surveilling rival hubs and investigating independent pharmacies that partnered with them.
Internal Findings and Company Response
The committee's report suggests that CVS's actions may constitute a violation of antitrust laws. CVS's initial justification for its conduct was to combat fraud within the hub system; however, the report claims the company provided no supporting evidence for these allegations. Furthermore, CVS asserted that it aimed to remove overpriced drugs from its formulary to lower costs for patients and plan sponsors. Internal documents, however, indicated that CVS pressured independent pharmacies to cease dispensing certain medications through audits and cease-and-desist orders.
In response to the investigation, CVS spokesperson David Whitrap stated, “We are reviewing the report,” and emphasized that the company is not opposed to innovative models that enhance patient experiences. He noted that CVS updated its provider manual in May 2025 to facilitate independent pharmacies' use of hubs.
Implications for Competition and Consumers
The committee's findings highlight that CVS's behavior complicates pharmacies' ability to collaborate with hubs, thereby depriving consumers of potential benefits from these innovations and creating barriers for CVS's competitors. The report indicates that CVS only began to modify its provider manual to allow independent pharmacies to work with hubs without restrictions after the investigation commenced. However, these changes have yet to be fully realized, raising concerns that CVS could revert to more restrictive practices in the future.
The disruption caused by CVS's actions not only bolstered the company's profits but also adversely affected consumers. The report underscores the significant role of PBMs, which serve as intermediaries between insurers, drug manufacturers, and pharmacies. The "big three" PBMs—CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx—control approximately 60 percent of the market and have faced criticism for inflating the costs of essential medications, including those for heart disease and cancer.
Verbatim Quotes
- “In 2019, CVS Health developed a plan to invest heavily in the digital pharmacy sector after facing intense competition from the likes of PillPack, Phil, and Blink.” — House Judiciary Committee Report
- “It is possible that CVS Health’s conduct violated the antitrust laws,” — House Judiciary Committee Report
- “makes it more difficult for pharmacies to choose to work with hubs, deprives consumers of the benefits of these innovations, and creates barriers to entry for potential CVS Health competitors.” — House Judiciary Committee Report
Conflicting Reports & Gaps
While the committee's report suggests that CVS Health's actions may have violated antitrust laws, CVS has not confirmed any wrongdoing and maintains that it is reviewing the findings. The lack of evidence supporting CVS's claims of fraud within the hub system remains a point of contention. Additionally, the timeline for the implementation of changes to the provider manual is unclear, leaving questions about CVS's future practices.
